Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica’s Microbiome-Based Immuno-Oncology Drug

Biomica expects to initiate first-in-human, proof-of-concept study later this year

 

Rehovot & Haifa, Israel – October 27, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and Rambam Health Care Campus today announced the signing of a clinical trial agreement (CTA) for initiating a first in-human proof-of-concept (POC) for BMC128,

Biomica To Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021 (Virtual Conference)

Rehovot, Israel – April 19, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday,

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

Biomica’s live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

 

Rehovot, Israel – April 13, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces Participation at the 5th Microbiome Movement Drug Development Europe Conference on January 28-29, 2021 (Virtual Conference)

Rehovot, Israel – January 20, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference. 

Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program

The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next year

Rehovot, Israel – October 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN),

Biomica Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

Rehovot, Israel – September 9, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference. 

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

Biomica’s, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year

Rehovot, Israel – September 8, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,